Month: April 2017

Chemoresistance in breast cancer is associated with the modulation of tumor cell populations

Researchers from the transformation and metastasis group of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Eva González-Suárez, have been able to recreate and characterize the process of acquisition of resistance to chemotherapy in orthotopic animal models of breast cancer, unveiling the possibility of reversing this resistance after a period of rest from the …

Chemoresistance in breast cancer is associated with the modulation of tumor cell populations Read More »

IDIBELL researchers look for new drugs against melanoma

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) participated in a study published recently in the by the journal Investigative Dermatology, entitled “AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK / ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact …

IDIBELL researchers look for new drugs against melanoma Read More »

Bellvitge research receives 1 million euros in PERIS 2016-2020 funding

The Department of Health has issued the final resolution of the first call for research grants linked to the Strategic Plan for Research and Innovation in Health (PERIS) 2016-2020. Researchers from the University Hospital of Bellvitge (HUB), the Catalan Institute of Oncology (ICO) and the University of Barcelona (UB) and their research projects, managed through …

Bellvitge research receives 1 million euros in PERIS 2016-2020 funding Read More »

Scroll to Top